
**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**
Washington, D.C. 20549

SCHEDULE 13G

**Under the Securities Exchange Act of 1934
(Amendment No.)***

Bionano Genomics, Inc

(Name of Issuer)

Common Stock
(Title of Class of Securities)

09075F107
(CUSIP Number)

August 21, 2018
(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

- Rule 13d-1(b)
 Rule 13d-1(c)
 Rule 13d-1(d)

* The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

(1)	Names of reporting persons WEALTH STRATEGY HOLDING LIMITED	
(2)	Check the appropriate box if a member of a group (see instructions) (a) <input type="checkbox"/> (b) <input type="checkbox"/>	
(3)	SEC use only	
(4)	Citizenship or place of organization HONG KONG SAR	
Number of shares beneficially owned by each reporting person with:	(5)	Sole voting power 1,950,000 ¹
	(6)	Shared voting power
	(7)	Sole dispositive power 1,950,000 ¹
	(8)	Shared dispositive power
(9)	Aggregate amount beneficially owned by each reporting person 1,950,000	
(10)	Check if the aggregate amount in Row (9) excludes certain shares (see instructions) <input type="checkbox"/>	
(11)	Percent of class represented by amount in Row (9) 15.13%	
(12)	Type of reporting person (see instructions) FI	

¹ By virtue of being the controlling shareholder and/ / or director of the Reporting Person, Mr. Kung Hung Ka may be deemed to have sole voting and dispositive power with respect to these shares.

Item 1.

- (a) **Name of Issuer:**
Bionano Genomics, Inc
- (b) **Address of Issuer's Principal Executive Offices:**
9540 Towne Centre Drive, Suite 100
San Diego, California 92121

Item 2.

- (a) **Name of Person Filing:**
WEALTH STRATEGY HOLDING LIMITED
- (b) **Address of Principal Business Office or, if none, Residence:**
WEALTH STRATEGY HOLDING LIMITED
Level 12,
International Commerce Centre,
1 Austin Road West,
Kowloon, Hong Kong
- (c) **Citizenship:**
Hong Kong
- (d) **Title of Class of Securities:**
Common Stock
- (e) **CUSIP Number:**
09075F107

- Item 3. If this statement is filed pursuant to §§ 240.13d-1(b) or §§ 240.13d-2(b) or (c), check whether the person filing is a:**
Not Applicable

Item 4. Ownership:

- (a) **Amount beneficially owned:**
975,000 shares, including warrants to acquire 975,000 shares
- (b) **Percent of class:**
15.13%
- (c) **Number of shares as to which such person has:**
- (i) Sole power to vote or to direct the vote: 1,950,000
 - (ii) Shared power to vote or to direct the vote:
 - (iii) Sole power to dispose or to direct the disposition of: 1,950,000
 - (iv) Shared power to dispose or to direct the disposition of:
-

- Item 5. Ownership of Five Percent or Less of a Class:**
If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following [].
- Item 6. Ownership of More than Five Percent on Behalf of Another Person:**
Not Applicable
- Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person:**
Not Applicable
- Item 8. Identification and Classification of Members of the Group:**
Not Applicable
- Item 9. Notice of Dissolution of Group:**
Not Applicable
- Item 10. Certifications:**
Not Applicable
-

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

December 14, 2018
Date

/s/ Ken Tsang
Ken Tsang

Title: Compliance Officer